Hyaluronic acid (HA) injections have become one of the most widely used minimally invasive therapies for joint health. The global market has grown rapidly, creating significant opportunities for distributors.
The global HA injection market is projected to grow at a CAGR of 8–10% between 2023–2030. This expansion is driven by the aging population and the rising prevalence of osteoarthritis.
Asia-Pacific: Demand is surging, particularly in China, South Korea, and India.
Middle East: Healthcare investments and awareness of joint health are fueling growth.
Latin America: Countries like Brazil and Mexico are seeing increased demand due to aging populations.
Certification: CE certification is sufficient for most non-FDA markets. ORTHOSYN provides CE-certified products, ensuring compliance and trust.
High Stock Capacity: ORTHOSYN can ship up to 500 units within 1–3 business days.
Product Variety: From 20 mg, 32 mg, 40 mg, 48 mg (linear) to 72 mg, 90 mg (cross-linked), the portfolio covers diverse clinical needs.
The global HA injection market continues to expand. Distributors who align with trusted manufacturers like ORTHOSYN can leverage strong demand, certified products, and fast logistics to achieve sustainable growth.